Efficacy and tolerability of adjuvant perampanel: an Australian multicenter real-world observational study in refractory focal and generalized epilepsy syndromes
Parveen Sagar, Olivia Wawryk, Sara Vogrin, Emma Whitham, Michelle Kiley, Joseph Frasca, Ross Carne, Udaya Seneviratne, Mark J Cook, Nicholas Lawn, Armin Nikpour, Wendyl Jude D'Souza
EPILEPSY & BEHAVIOR | ACADEMIC PRESS INC ELSEVIER SCIENCE | Published : 2021
PURPOSE: To explore the efficacy and tolerability of adjuvant perampanel (PER) and their associated risk factors in late add-on drug-resistant epilepsy. METHOD: Retrospective multicenter 'real-world' observational study. Consecutively identified patients commenced on PER, with mixed epilepsy syndromes, from nine Australian epilepsy centers. Primary efficacy endpoints were at least 50% reduction in seizure frequency (responders), seizure freedom, and retention at 6 and 12 months, following a 3-month titration period. Tolerability endpoints were cessation of PER for any reason, cessation of PER due to treatment-emergent adverse events (TEAE), or cessation due to inefficacy. Outcomes were asses..View full abstract
Awarded by Eisai
This work was supported by Eisai (Protocol Number: HREC/18/SVHM/142) . Eisai was not involved in the study design, the collection, analysis and interpretation of the data gathered, the writing of the report, or the decision to submit the article for publication. Wendyl D'Souza's salary is part funded by The University of Melbourne. He has received travel, investigatorinitiated, scientific advisory board and speaker honoraria from UCB Pharma Australia & Global; investigatorinitiated, scientific advisory board, travel and speaker honoraria from Eisai Australia & Global; advisory board honoraria from Liva Nova and Tilray; educational grants from Novartis Pharmaceuticals, Pfizer Pharmaceuticals and SanofiSynthelabo; educational; travel and fellowship grants from GSK Neurology Australia, and honoraria from SciGen Pharmaceuticals. He has an equity interest in the device company EpiMinder and health software company KeyLead Health. Udaya Seneviratne has received travel and speaker honoraria from Eisai Australia and LivaNova Australia. Nicholas Lawn has received research funding support and consultancy fees/speaker honorariums from UCB and Eisai. This research funding is unrelated to this study. Armin Nikpour has received honorarium for advisory Board for UCB.